ASH 2022: MCL Trials Break New Ground, May Change Practice Mantle cell lymphoma trials presented at ASH 2022 have broken new ground, shown promising results, and may change practice, according to researchers.
ASH 2022: New Findings in CLL Research in patients with CLL showed that zanubrutinib can outperform ibrutinib, a triplet is effective for high-risk CLL, cell death may predict the depth of response, and a CAR T-cell therapy is likely not an option for CLL patients.
ASH 2022: Trials Show Promising Results in Follicular Lymphoma Results from 4 trials presented at ASH 2022 may help inform the treatment of newly diagnosed and relapsed/refractory follicular lymphoma.
Breast Implant-Associated Cancers: What Providers and Patients Need to Know Patients with breast implants are at risk of developing squamous cell carcinoma and various types of lymphoma in the capsules around the implants.
Blood Test Shows Promise for Detecting Cancers Without Approved Screening Tests A novel blood test can detect cancers that currently have no standard screening procedures, a study suggests.
Posoleucel Deemed Effective Against Viral Infections in Allogeneic HSCT Recipients Publish Date January 13, 2023
Outcomes Superior With Peripheral Blood vs Bone Marrow Transplants in PTCL Publish Date January 13, 2023